Clinical trials: Fever
Cardiovascular System, Respiratory System
Acute Health Effects of High Temperature Exposure
This is a randomized controlled human exposure crossover study. Investigators aims to assess the acute effects of high temperature exposure and the underlying mechanisms.
- Conditions
- Cardiovascular System, Respiratory System, Cognitive Function
- Trial name
- NCT05575752
- Testing
- high temperature (32℃) group, moderate temperature (22℃) group
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fudan University
Fever, Healthy
Clinical Performance of Masimo INVSENSOR00048
The objective of this clinical study is to validate temperature performance of the noninvasive Masimo INVSENSOR00048.
- Trial name
- NCT06289556
- Testing
- Masimo INVSENSOR00048
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Masimo Corporation
Dengue Fever
Bridging Economics and Public Trust: A Study of Dengue Vaccine Cost-effectiveness and Acceptance in Thais Visiting Hospital
Study 1: Cost-effectiveness of TAK-003 Dengue Vaccination in Thailand This study aims to evaluate the cost-effectiveness of introducing the live-attenuated tetravalent dengue vaccine (TAK-003) into Thailand's national…
- Trial name
- NCT07759596
- Testing
- Objective 1- economic evaluation of Thai children with dengue vaccine
- Where
- Thailand
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Chikungunya Virus Infection
A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years
This is a multicenter, prospective, randomized, observer-blinded, three arm, phase 2 clinical trial evaluating the full dose formulation of VLA1553, half dose formulation of VLA1553 and control.
- Trial name
- NCT06106581
- Testing
- VLA1553 full dose, VLA1553 half dose, Control
- Where
- 3 sites in Dominican Republic, Honduras
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Yellow Fever (Healthy Volunteers), Biopsy/Methods
Baseline Assessment of Skin Resident Memory T Cells in Healthy Unvaccinated Participants
In The main GeKoSkimm trial (= A randomized controlled trial to compare the immunogenicity and skin imprinting of intradermal, subcutaneous and intramuscular yellow fever vaccination) the investigators try to understand whether…
- Trial name
- NCT07636551
- Testing
- Skin punch biopsy, Blood samples
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Chikungunya Virus Infection
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination
The purpose of this phase 3 multicenter, randomized, double-blind, placebo-controlled rollover study is to evaluate the safety and long-term immunogenicity of CHIKV VLP vaccine in adult and adolescent participants and to evaluate…
- Trial name
- NCT06007183
- Testing
- CHIKV VLP vaccine booster
- Where
- 24 sites in United States
- Volunteers
- 715 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Dengue, Dengue Hemorrhagic Fever
Gut Leakage' in Dengue
Dengue infections are imposing an increasing global burden of disease, particularly in tropical countries such as Bangladesh. The World Health Organization (WHO) has identified Dengue virus as a priority pathogen for the…
- Conditions
- Dengue, Dengue Hemorrhagic Fever, Intestinal Disease, Ascites
- Trial name
- GLiD (NCT07602920)
- Where
- Bangladesh
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Dengue Fever
Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose
The purpose of this study is to describe antibody persistence for each of the 4 dengue serotypes for up to 63 months after the first vaccination in the primary vaccination series for participants from parent trial DEN-315…
- Trial name
- NCT03999996
- Testing
- Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)
- Where
- 10 sites in United States, Mexico
- Volunteers
- 365 people, healthy volunteers welcome
- Sponsor
- Takeda
Chikungunya Virus Infection
Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil
This is an observational study with primary data collection, which will combine a prospective safety cohort study and an SCRI study.
- Trial name
- NCT07254702
- Testing
- Live-attenuated CHIKV vaccine VLA1553
- Where
- 3 sites in Brazil
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Chikungunya Virus Infection
VLA1553-403 Pregnancy Surveillance Study
This post-marketing, observational study evaluates pregnancy and infant outcomes up to 12 weeks after delivery among women who received the chikungunya vaccine (VLA1553) during pregnancy or within 30 days before their last…
- Trial name
- NCT07414524
- Testing
- Live-attenuated CHIKV vaccine VLA1553, Vaccine(s) approved for use during pregnancy by the MoH
- Where
- 3 sites in Brazil
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Dengue Fever With Warning Signs
Phase 3b Trial To Evaluate Safety And Immune Response (Superiority) of a Two-Dose Butantan-DV Regimen And The Standard Single Dose In Dengue-Naive Children/Adolescents and Immune Response (Non-inferiority) in a Manufacturing Facility Change (DEN-06-IB)
This randomized, double-blind, three parallel-group, multicenter, phase 3b trial evaluates the safety and immunogenicity of Butantan-DV. The study compares two primary immunization regimens (Butantan-DV/Butantan-DV vs.
- Trial name
- DEN-06-IB (NCT07712926)
- Testing
- Butantan-DV (IB), Butantan-DV (WuXi)
- Volunteers
- 1,765 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Dengue Fever
A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults
Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever.
- Trial name
- NCT07047521
- Testing
- Tetravalent Dengue Vaccine (TDV)
- Where
- 5 sites in Australia
- Volunteers
- 496 people, healthy volunteers welcome
- Sponsor
- Takeda
Chikungunya Virus Infection
Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil
This is an observational, non-interventional, test-negative case-control (TNCC) study to estimate the vaccine effectiveness of VLA1553 against Chikungunya virus in a real-world setting.
- Trial name
- NCT07347002
- Testing
- Live-attenuated CHIKV vaccine VLA1553
- Where
- 3 sites in Brazil
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Dengue, Chikungunya
Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.
This randomized, controlled, double blind trial aims at assessing the safety and immunogenicity profiles of the co-administered Live Attenuated Dengue and Chikungunya vaccines comparatively to the isolated administration, in the…
- Trial name
- NCT06973772
- Testing
- DENGUE: Dengue 1,2,3,4 (attenuated) vaccine CHIKUNGUNYA: Chikungunya (CHIKV) live attenuated vaccine (VLA1555), DENGUE: Dengue 1,2,3,4 (attenuated) vaccine, Chikungunya (CHIKV) live attenuated vaccine (VLA1555)
- Where
- 7 sites in Brazil
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Ebola Virus Disease
Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola
This Phase 2 study aims to improve preparedness for future Ebola outbreaks by vaccination of a well-known population at risk, ie, a cohort of health care providers (HCP) (such as primary, emergency, and community health care…
- Trial name
- EBOVAC3DRC (NCT04186000)
- Testing
- Ad26.ZEBOV vaccine
- Where
- Democratic Republic of the Congo
- Volunteers
- 699 people, healthy volunteers welcome
- Sponsor
- Universiteit Antwerpen
Chikungunya Virus Infection
Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)
In this open-label Phase 3b, single arm trial, persistence of antibodies and long term safety will be evaluated in up to 375 participants rolled over from trial VLA1553-301 (NCT number: NCT04546724).
- Trial name
- NCT04838444
- Testing
- VLA1553
- Where
- 10 sites in United States
- Volunteers
- 363 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Hemorrhagic Fever
Treatment of Hemorrhagic Fever With Ribavirin
Multisite protocol to provide IV Ribavirin treatment to patients with probable or suspected case of Hemorrhagic Fever with Renal Syndrome (HFRS)
- Trial name
- NCT04283513
- Testing
- Virazole
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Fever, Pain
Bioequivalence Study of Paracetamol With Oral Single Dose Administration in Healthy Adult Subjects Under Fasting Conditions
This study aims to evaluate the bioequivalence of new formulated orodispersible tablet (ODT) containing 500 milligram (mg) paracetamol in comparison to the European marketed Alvedon (paracetamol) 500 mg film-coated tablets and…
- Trial name
- NCT06855576
- Testing
- Paracetamol ODT, Alvedon film-coated tablet, Panadol film-coated Tablet
- Where
- Germany
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- HALEON
Dengue Fever
A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers
Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever.
- Trial name
- NCT06665035
- Testing
- TDV
- Where
- 4 sites in Colombia, Thailand
- Volunteers
- 212 people, healthy volunteers welcome
- Sponsor
- Takeda
Chikungunya Virus
An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults
Study EBSI-CV-317-007 is a field study to evaluate the efficacy, immunogenicity, and safety of CHIKV VLP vaccine. The study was designed using infectious disease models and advanced analytics to guide region and clinical site…
- Trial name
- NCT07467707
- Testing
- CHIKV VLP vaccine
- Where
- 3 sites in Philippines, Thailand
- Volunteers
- 6,144 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic